Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024
February 20 2024 - 7:00AM
Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a
commercial-stage biotechnology company, will report its fourth
quarter and full year 2023 financial results on Monday,
February 26, 2024, prior to the open of U.S. markets. Subsequently,
at 8:30 am ET, the Company will host a webcast to discuss the
financial results and provide a business update.
Investor Conference Call
The Company will host an investor webcast on Monday,
February 26, 2024 at 8:30 am ET.
Investors and the general public can access the live webcast at
https://www.webcaster4.com/Webcast/Page/3018/49928.
For those unable to listen to the live webcast, a replay will be
available for 30-days on the Investors section of the Company’s
website at www.krystalbio.com.
About Krystal Biotech, Inc.Krystal Biotech,
Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company
focused on the discovery, development and commercialization of
genetic medicines to treat diseases with high unmet medical needs.
VYJUVEK® is the Company’s first commercial product, the first-ever
redosable gene therapy, and the first medicine approved by the FDA
for the treatment of dystrophic epidermolysis bullosa. The Company
is rapidly advancing a robust preclinical and clinical pipeline of
investigational genetic medicines in respiratory, oncology,
dermatology, ophthalmology, and aesthetics. Krystal Biotech is
headquartered in Pittsburgh, Pennsylvania. For more information,
please visit http://www.krystalbio.com, and follow @KrystalBiotech
on LinkedIn and X (formerly Twitter).
CONTACTInvestors and Media:
Meg Dodge
Krystal Biotech
mdodge@krystalbio.com
Krystal Biotech (NASDAQ:KRYS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Krystal Biotech (NASDAQ:KRYS)
Historical Stock Chart
From Oct 2023 to Oct 2024